Seroatlas · Human Serome Atlas

FGF8

Fibroblast growth factor 8

Also known as: AIGF, FGF8_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession
P55075
Gene
FGF8
Ensembl
ENSG00000107831
Chromosome
10
Canonical length
233 aa
Protein class
Cancer-related genes, Disease related genes, Human disease related genes, Predicted intracellular proteins, Predicted secreted proteins, RAS pathway related proteins
Secretome location
Secreted in other tissues
Quaternary structure
Homodimer

OverviewNCBI Gene

The protein encoded by this gene is a member of the fibroblast growth factor (FGF) family. FGF family members possess broad mitogenic and cell survival activities, and are involved in a variety of biological processes, including embryonic development, cell growth, morphogenesis, tissue repair, tumor growth and invasion. This protein is known to be a factor that supports androgen and anchorage independent growth of mammary tumor cells. Overexpression of this gene has been shown to increase tumor growth and angiogensis. The adult expression of this gene is restricted to testes and ovaries. Temporal and spatial pattern of this gene expression suggests its function as an embryonic epithelial factor. Studies of the mouse and chick homologs revealed roles in midbrain and limb development, organogenesis, embryo gastrulation and left-right axis determination. The alternative splicing of this gene results in four transcript variants. [provided by RefSeq, Jul 2008]

Canonical amino-acid sequenceUniProt

233 residues, UniProt reviewed canonical sequence.

>P55075|FGF8
     1  MGSPRSALSC LLLHLLVLCL QAQEGPGRGP ALGRELASLF RAGREPQGVS QQHVREQSLV
    61  TDQLSRRLIR TYQLYSRTSG KHVQVLANKR INAMAEDGDP FAKLIVETDT FGSRVRVRGA
   121  ETGLYICMNK KGKLIAKSNG KGKDCVFTEI VLENNYTALQ NAKYEGWYMA FTRKGRPRKG
   181  SKTRQHQREV HFMKRLPRGH HTTEQSLRFE FLNYPPFTRS LRGSQRTWAP EPR

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against FGF8 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability
Secreted
Secreted
Yes
Transmembrane segments
0
Mean surface accessibility (rSASA)
0.41
Highest tissue expression
33 nTPM

Expression across tissuesHPA

Tissue

  • skeletal muscle: 33 nTPM
  • testis: 0.7 nTPM
  • cerebral cortex: 0.6 nTPM
  • esophagus: 0.5 nTPM
  • hippocampal formation: 0.5 nTPM
  • hypothalamus: 0.5 nTPM

Single-cell type

  • retinal ganglion cells: 3.9 nCPM
  • adipocytes: 2.8 nCPM
  • breast myoepithelial cells: 1.7 nCPM
  • cholangiocytes: 1.3 nCPM
  • myosatellite cells: 1.2 nCPM
  • late spermatids: 0.9 nCPM

Immune cell

  • basophil: 1.4 nTPM
  • neutrophil: 0.8 nTPM
  • non-classical monocyte: 0.7 nTPM
  • NK-cell: 0.5 nTPM
  • eosinophil: 0.4 nTPM
  • intermediate monocyte: 0.4 nTPM

Brain region

  • cerebral cortex: 2.4 nTPM
  • hypothalamus: 2.4 nTPM
  • hippocampal formation: 2.1 nTPM
  • white matter: 2 nTPM
  • amygdala: 1.7 nTPM
  • choroid plexus: 1.7 nTPM

DiseaseUniProt · ClinVar · IEDB · PubMed

Four sources answering four different questions about FGF8.

Disease | AllUniProt

Conditions FGF8 is implicated in, by any mechanism.

  • Hypogonadotropic hypogonadism 6 with or without anosmia (HH6) MIM:612702
  • Hypoplastic femurs and pelvis (HYPOFP) MIM:619545

Disease | GeneticClinVar

18 pathogenic / likely-pathogenic of 135 ClinVar records.

Conditions with pathogenic or likely-pathogenic variants.

ReferencesPubMed · IEDB

Publications for FGF8 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.

Reference: AutoantibodyPubMed

1 publication

Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance)
0.51
gnomAD pLI
0.68
gnomAD missense Z
1.57
DepMap mean gene effect
0
DepMap dependency class
selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

InteractionsUniProt · HPA

Protein binding partners of FGF8 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads FGF8 as an antibody target. Whether an autoantibody or antibody against FGF8 could matter depends on whether native FGF8 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

FGF8 is annotated as secreted, so native FGF8 circulates and is directly accessible to antibodies. Secreted and cell-surface proteins are the autoantibody targets most likely to act like drugs, blocking or depleting the native protein.

Annotation status

The present source text does not explicitly label FGF8 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Canonical record: https://seroatlas.com/gene/FGF8. Study-independent annotations aggregated from UniProt, Human Protein Atlas, PubMed, IEDB, Pfam, InterPro, Gene Ontology, AlphaFold, gnomAD, DepMap, ClinVar, TCGA. Catalog release seroatlas-reviewed-human-uniprot-20260313.

Seroatlas is the reference for exploring autoantibody and antibody serology at the human-protein level: the autoreactome and human serome, multiplex serology (HuProt, HuScan, VirScan, PhIP-Seq).

© 2026 · Seroatlas, Discover Oregon LLC · Terms of use

Loading the interactive Seroatlas protein explorer...